Table 1.

Characteristics of 33 relapsed lung ADC patients with SCLC transition

Patient ID	Gender	Age	Smoking status	Therapy	1st biopsya		2nd biopsyb		References
					Pathological status	Mutation status	Pathological status	Mutation status
1	M	54	NA	TKI	ADC	EGFR 19 del	SCLC	EGFR 19 del	[32]
2	F	56	NA	TKI	ADC	EGFR 19 del	SCLC	EGFR 19 del	[32]
3	F	61	NA	TKI	ADC	EGFR 19 del	SCLC	EGFR 19 del	[32]
4	F	72	N	Gef	ADC	EGFR 19 del	SCLC	EGFR 19 del	[91]
5	F	46	N	Erl	ADC	EGFR 19 del	SCLC	EGFR 19 del	[92]
6	F	52	N	Erl	ADC	EGFR 19 del	SCLC	EGFR 19 del	[93]
7	M	80	N	Ico	ADC	EGFR 19 del	SCLC	EGFR 19 del	[94]
8	F	63	N	Erl	ADC	EGFR 19 del	SCLC	EGFR 19 del	[95]
9	M	46	Y	Gef	ADC	EGFR 19 del	SCLC	EGFR 19 del	[96]
10	M	49	Y	Erl	ADC	EGFR 19 del and FGFR3 exon 17 deletion	SCLC	EGFR 19 del and FGFR3 exon 17 deletion	[97]
11	F	60	N	Gef	ADC	EGFR 19 del	SCLC	EGFR 19 del	[98]
12	M	65	N	Afa	ADC	EGFR 19 del	SCLC	EGFR 19 del	[99]
13	F	37	N	Gef	ADC	EGFR 19 del	SCLC	EGFR 19 del + T790M	[100]
14	F	42	N	Erl	ADC	EGFR 19 del	SCLC	EGFR 19 del + T790M	[101]
15	F	49	N	Gef	ADC	EGFR 19 del	SCLC	NA	[102]
16	M	41	Y	Gef	ADC	EGFR 19 del	SCLC + SCC	NA	[61]
17	M	74	Y	Gef	ADC	EGFR 19 del	SCLC	WT	[103]
18	F	48	NA	TKI	ADC	EGFR L858R	SCLC	EGFR L858R	[32]
19	F	67	NA	TKI	ADC	EGFR L858R	SCLC	EGFR L858R	[32]
20	F	72	N	Gef	ADC	EGFR L858R	SCLC	EGFR L858R	[104]
21	M	46	N	Gef	ADC	EGFR L858R	SCLC	EGFR L858R	[105]
22	M	49	Y	Gef	ADC	EGFR L858R	SCLC	EGFR L858R	[106]
23	F	65	N	Gef	ADC	EGFR L858R	SCLC	EGFR L858R	[107]
24	M	73	NA	Gef	ADC	EGFR L858R	SCLC	EGFR L858R	[108]
25	F	40	NA	TKI	ADC	EGFR L858R	SCLC	EGFR L858R and PIK3CA	[32]
26	M	38	N	Erl	ADC	EGFR L858R	SCLC	NA	[109]
27	M	72	Y	Crizo	ADC	ALK	SCLC	ALK	[33]
28	M	67	N	Alec	ADC	ALK	SCLC	ALK	[34]
29	F	72	N	Gef	ADC	WT	SCLC	NA	[35]
30	M	61	N	TKI	ADC	NA	SCLC	EGFR 19 del	[110]
31	F	46	N	Gef	ADC	NA	SCLC	EGFR 19 del	[111]
32	F	45	N	Erl- Gef	ADC	NA	SCLC	EGFR 19 del	[31]
33	F	73	N	Gef	ADC	NA	SCLC	EGFR L858R	[104]

Y yes, N no, NA not available, M male, F female, ADC adenocarcinoma, SCC squamous cell carcinoma, SCLC small cell lung cancer, TKI tyrosine kinase inhibitor, Gef gefitinib, Erl erlotinib, Ico icotinib, Afa afatinib, Crizo crizotinib, Alec alectinib, EGFR epidermal growth factor receptor, EGFR 19 del EGFR exon 19 deletion, ALK anaplastic lymphoma kinase, WT wild-type

^a1st biopsy: the first biopsy

^b2nd biopsy: the second biopsy